AstraZeneca Vaccine’s ‘Big Gap’: DSMB Questions Results Released By Firm In Latest Controversy

‘Harsh note’ from Data Safety and Monitoring Board follows AstraZeneca press release that contained incomplete information about the Phase III US trial for its COVID vaccine. It remains to be seen how the company will fix this ‘unforced error’ and weather the latest threat to public trust.

AZ vaccine
AstraZeneca criticized for incomplete COVID-19 vaccine trial data • Source: Shutterstock

If there’s no such thing as bad publicity, AstraZeneca PLC’s COVID-19 vaccine is doing great, having generated a series of embarrassing events surrounding the rollout in Europe and development in the US.

Now, in an extraordinary move, the Data and Safety Monitoring Board overseeing the US clinical trial has voiced concerns about...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet